Zhang Wenyong W, Habeebu Sultan, Sheehan Andrea M, Naeem Rizwan, Hernandez Vivian S, Dreyer Zoann E, López-Terrada Dolores
Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
J Pediatr Hematol Oncol. 2009 Nov;31(11):879-83. doi: 10.1097/MPH.0b013e3181b83fd0.
The 8p11 myeloproliferative syndrome is a rare hematologic malignancy derived from a pluripotent hematopoietic stem cell associated with rearrangements involving the fibroblast growth factor receptor 1 (FGFR1) gene located on chromosome 8p11. The most common translocation, t(8;13) (p11;q13), results in a ZNF198-FGFR1 fusion gene and constitutively active FGFR1 tyrosine kinase activity. Typical pathologic findings include myeloid hyperplasia, lymphadenopathy, precursor T-lymphoblastic lymphoma, and eosinophilia. The disease is usually associated with an aggressive course and progression to acute myeloid leukemia is frequent. We report here the first case of 8p11 myeloproliferative syndrome in an infant and demonstrate the value of molecular testing in the diagnosis and minimal disease monitoring of this rare disease.
8p11骨髓增殖综合征是一种罕见的血液系统恶性肿瘤,起源于多能造血干细胞,与位于8号染色体p11区的成纤维细胞生长因子受体1(FGFR1)基因重排有关。最常见的易位是t(8;13) (p11;q13),导致ZNF198-FGFR1融合基因和持续激活的FGFR1酪氨酸激酶活性。典型的病理表现包括骨髓增生、淋巴结病、前体T淋巴细胞淋巴瘤和嗜酸性粒细胞增多。该疾病通常病程侵袭性强,常进展为急性髓系白血病。我们在此报告首例婴儿8p11骨髓增殖综合征病例,并展示分子检测在这种罕见疾病诊断和微小疾病监测中的价值。